Author

Sophie Ottema

Erasmus MC

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Bas J. WoutersiD· 1 shared Claudia A. J. Erpelinck-VerschuereniD· 1 shared Claudia HaferlachiD· 1 shared Dorien PastoorsiD· 1 shared Eric BindelsiD· 1 shared H. Berna BeverlooiD· 1 shared Johannes A. ZuberiD· 1 shared John E. PimandaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bas J. WoutersORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia

Dorien Pastoors, Marije Havermans, Roger Mulet‐Lazaro, Leonie Smeenk, Sophie Ottema, Claudia A. J. Erpelinck-Verschueren, Stanley van Herk, Maikel Anthonissen, Tim Grob, Shruthi Subramanian, Julie A.I. Thoms, John E. Pimanda, Bas J. Wouters, H. Berna Beverloo, Torsten Haferlach, , Ruud Delwel

This study shows MECOM represses myeloid differentiation by inhibiting CEBPA, and its overexpression in AML reduces CEBPA levels, maintaining stem cell state.

Blood · Oct 8, 2025Peer-reviewedCancer Biology